| Literature DB >> 33324495 |
Jake D Lehle1, John R McCarrey1.
Abstract
There is now considerable evidence indicating the potential for endocrine disrupting chemicals to alter the epigenome and for subsets of these epigenomic changes or "epimutations" to be heritably transmitted to offspring in subsequent generations. While there have been many studies indicating how exposure to endocrine disrupting chemicals can disrupt various organs associated with the body's endocrine systems, there is relatively limited information regarding the relative susceptibility of different specific organs, tissues, or cell types to endocrine disrupting chemical-induced epimutagenesis. Here we review available information about different organs, tissues, cell types, and/or cell lines which have been shown to be susceptible to specific endocrine disrupting chemical-induced epimutations. In addition, we discuss possible mechanisms that may be involved, or impacted by this tissue- or cell type-specific, differential susceptibility to different endocrine disrupting chemicals. Finally, we summarize available information indicating that certain periods of development display elevated susceptibility to endocrine disrupting chemical exposure and we describe how this may affect the extent to which germline epimutations can be transmitted inter- or transgenerationally. We conclude that cell type-specific differential susceptibility to endocrine disrupting chemical-induced epimutagenesis is likely to directly impact the extent to, or manner in, which endocrine disrupting chemical exposure initially induces epigenetic changes to DNA methylation and/or histone modifications, and how these endocrine disrupting chemical-induced epimutations can then subsequently impact gene expression, potentially leading to the development of heritable disease states.Entities:
Keywords: DNA methylation; developmental-stage specificity; environmental disruptors; epigenetic programing; epimutations; histone modifications; tissue-/cell type-specificity
Year: 2020 PMID: 33324495 PMCID: PMC7722801 DOI: 10.1093/eep/dvaa016
Source DB: PubMed Journal: Environ Epigenet ISSN: 2058-5888
list of endocrine disrupting chemicals
| Chemical | Structure | Use | Citation(s) |
|---|---|---|---|
| Dichlorodiphenyltrichloroethane (DDT) |
| Insecticide used in agriculture and banned in the USA in 1972. Trade names included Anofex, Cesarex, Chlorophenothane, Dedelo, Dinocide, Didimac, Digmar, ENT 1506, Genitox, Guesapon, Guesarol, Gexarex, Gyron, Hildit, Ixodex, Kopsol, Neocid, OMS 16, Micro DDT 75, Pentachlorin, Rukseam, R50, and Zerdane. Still in use outside of the USA for the control of mosquitoes and the spread of malaria. Human and animal exposure is linked to learning disabilities, breast cancer, and obesity | [ |
| Methoxychlor |
| Organochlorine pesticide intended to be a replacement for DDT but was banned in the USA in 2003 due to concerns over bioaccumulation toxicity and endocrine disruptor activity. Trade names include Marlate, Chemform, and Methoxy-DDT. Human and animal exposure is linked to learning disabilities, breast cancer, and obesity | [ |
| Atrazine |
| Currently one of the most widely available herbicides, used for the control of grass and broadleaf weeds. Marketed under the trade names AAtrex and Atranex | [ |
| Ioxynil (IOX) |
| Herbicide used for postemergence control of various broadleaf weeds. Marketed under the trade names Actril and Totril | [ |
| Vinclozolin (VZ) |
| Dicarboximide fungicide used to control agricultural blights, rots, and molds. Trade names include Ronilan, Curalan, Vorlan, and Touche. Has been shown to have antiandrogenic activity but can also bind to progesterone and estrogen receptors. Exposure in male rats can influence sexual differentiation, reproductive function, and cause transgenerationally maintained kidney and prostate disease | [ |
| Hexaclorobenzene (HCB) |
| Used as a fungicide to treat cereal crops to control the fungal disease bunt. Trade names include Anticarie, Ceku C.B., and No Bunt. Has also been used as a wood preservative, synthetic rubber peptizing agent, and for aluminum fluxing and degassing. Human exposure is linked to obesity | [ |
| Bisphenol A (BPA) |
| Starting material for synthesis of polycarbonate plastics and epoxy resins. Also found in thermal receipt paper, CDs and DVDs, and inside lining of tin cans. Animal exposure is linked to brain disorders, heart disease, diabetes, and breast or prostate cancer | [ |
| Bisphenol S (BPS) |
| Used to cure fast drying epoxy glues and as a corrosion inhibitor. Used as a BPA replacement in the production of plastics and epoxies and is now commonly found in many consumer goods | [ |
| Bisphenol F (BPF) |
| Used in manufacturing of plastics and epoxy resins. Typically found in tank and pipe linings, industrial floors, structural coatings, and adhesives | [ |
| Di(2-ethylhexyl) phthalate (DEHP) |
| Phthalate is used as a plasticizer to make plastics more flexible. Commonly found in a range of industrial and consumer products made with polyvinyl chloride (PVC). Trade names include Bisofex 81, Bisofex DOP, Celluflex DOP, Compound 889, Corfex 400, Diacizer DOP, Eviplast 80, Fleximel, Flexol DOP, HercoFlex, Kodaflex DOP, Palatinol AH, Plasticizer DOP, Sicol 150, Staflex DOP, and Truflex DOP. Human exposure is linked to infertility | [ |
| Diethylstilbestrol (DES) |
| Nonsteroidal estrogen medication banned in the USA in 1971. Two most commonly used brand names were Stilbestrol and DESPlex. Human exposure is linked to anatomical deformation of the reproductive tract and cancers | [ |
| Zearalenone (ZEN) |
| Estrogenic metabolite produced by some | [ |
| Decabromodiphenyl ether-209 (BDE-209) |
| Polybrominated diphenyl ether (PBDE) congener commonly used in the production of flame-retardant mixtures. Makes up 49.6% of the octa-PBDE marketed under the trade name Bromkal 79-8DE as well as 96.8% and 91.6% of the respective deca-PBDE products which have the trade names Saytex 102E and Bromkal 82-0DE | [ |
| 2,2’,4,4’-Tetrabromodiphenyl ether (BDE-47) |
| PBDE congeners are used in the commercial production of flame-retardant mixtures. BDE-47 makes up between 38.2% and 42.8% of the respective commercially available penta-PBDE products marketed under the trade names DE-71 and Bromkal 70-5DE. Animal exposure is linked to increased risk of obesity | [ |
| Tetrabromobisphenol A (TBBPA) |
| Second most commonly used brominated flame retardant in the USA and Canada behind PBDEs and followed by HBCD. Trade names include Great Lakes BA-59P, Saytex RB-100, Bromdian, Fire Guard 2000, Firemaster BP 4A, and Tetrabrom | [ |
| Hexabromocyclododecane (HBCD) |
| Brominated flame retardant used in polystyrene foams in thermal insulation and electrical equipment. Trade names include Bromkal 73-6CD, Myflam 11645, Pyroguard SR 103, Saytex HBCD, and SR 104. Stereoisomer contaminates can also commonly be found in packaged consumer foods | [ |
| P-n-nonylphenol (NP) |
| Antiandrogen and estrogenic alkylphenol that originates from the degradation of nonylphenol ethoxylates which are used widely as industrial surfactants. Has also been found in soft drinks and dairy products. Animal exposure is linked to brain disorders | [ |
| P-n-octylphenol (OP) |
| Estrogenic alkylphenol that originates from degradation of industrial surfactants. Has also been found as a contaminant in water as well as soft drinks and dairy products | [ |
| 2,3,7,8-Tetrachlorodibenzo-[p]-dioxin (TCDD) |
| Highly potent congener of the polychlorinated dibenzodioxins (PCDDs) or simply referred to as “dioxins.” A byproduct of producing certain chlorophenols or chlorophenoxy acid herbicides and burning or organic materials. Human exposure is linked to autoimmune disease, breast cancer, and endometriosis | [ |
| 2,2’,4,4’,5,5’-Hexachlorobiphenyl (PCB-153) |
| Manufactured in the USA between 1930 and 1977 for use in coolants and lubricants in electrical equipment such as capacitors and transformers as well as in pigments, dyes, and carbonless copy paper. Trade names include Aroclor and Chlorextol. Human exposure is linked to infertility, endometriosis, learning disabilities, stroke, and Parkinson’s disease | [ |
| Perfluorinated octyl acid (PFOA) |
| Used in a variety of applications since the 1940s primarily as an additive in the manufacturing of fluoropolymers which include products, such as Teflon® non-stick cookware and Gore-Tex® textiles | [ |
| Perfluorinated octyl sulfonate (PFOS) |
| Used in a wide range of applications. Was the key ingredient in Scotchgard® produced by 3M until phaseout efforts began in 2000 | [ |
| Tributyltin (TBT) |
| Organotins have been used in a variety of applications including as pesticides, herbicides, and as antifouling agents added to paints intended to protect boat hulls from the formation of rust. Trade names include Alumacoat, Bioclean, FloTin, Fungitrol, TinSan, Ultrafresh, and Vikol. Animal exposure is linked to obesity | [ |
in vitro and ex vivo studies of EDC-induced DNA methylation epimutations
| Chemical(s) |
| Concentration/length of exposure | Phenotypic effect(s) | Pathway(s)/mechanism(s) | Citation(s) |
|---|---|---|---|---|---|
| BDE-47 | Mouse 3T3-L1 preadipocyte fibroblasts | 3–25 nM/8 days | Increased adipocyte differentiation. Decreased methylation at promoter of | Activation of PPARγ but not RXR leads to decreased promoter methylation of | [ |
|
TRO TBT BDE-47 BPA TCDD HCB DES PFOA PFOS PCB-153 HBCD | Mouse N2A and human SK-N-AS neuroblastoma cells and mouse 3T3-L1 preadipocyte fibroblasts |
N2A and SK-N-AS cells— DES: 10 µM; BPA: 10 µM TCDD: 10 µM; BDE-47: 10 µM PCB-153: 10 µM; PFOS: 10 µM PFOA: 10 µM; HBCD: 10 µM HCB: 1 µM; TBT: 0.1 µM /48 h each | DES, BPA, TCDD, BDE-47, PCB-153, and HCB led to global decrease in DNA methylation, in N2A cells but not SK-N-AS cells | Not described | [ |
|
3T3-L1 cells— TRO: 1 µM; TBT: 10 nM, 50 µM BDE-47: 2.5, 12.5, 25 µM; BPA: 10, 50, 80 µM TCDD: 0.1, 0.5, 1 nM; HCB: 1, 5, 10 µM DES: 10 µM; PFOA: 10 µM PFOS: 10 µM; PCB-153: 3.4 µM HBCD: 10 µM /8 days each | TRO and 50 µM TBT led to global decreases in DNA methylation; 80 µM BPA led to global increase in DNA methylation in 3T3-L1 adipocytes. TRO, TBT, BDE-47, DES, PFOA, and PCB-153 exposure promoted adipocyte differentiation. TCDD exposure led to global decrease in adipocyte differentiation | ||||
|
BPA BPS | Human HTR8/SVneo first trimester trophoblast cells and human EA.hy926 vascular endothelial cells | 0.01–1 nM/24 h | BPA and BPS inhibited cell growth, proliferation, and tube formation in HTR8/SVneo cells. BPA decreased DNA methylation at the promoters of genes involved in cell cycle, proliferation, DNA replication, antioxidant and heat shock proteins, and stress and metabolism in HTR8/SVneo cells, except for | DNA methylation changes lead to downregulation of angiogenesis genes VEGF, PCNA, and ICAM1. No change in DNA methylation at these gene promoters | [ |
| BPA | GC-2 mouse spermatocytes | 20, 40, 80 µM/48 h | Global increase in DNA methylation, increased expression of | Variations in DNA methylation patterns are mediated through ER signaling | [ |
|
BPA DEHP | Porcine oocytes |
BPA: 200, 250 µM/26 h DEHP: 250 µM, 500 µM, 750 µM, 1 mM, 5 mM/26 h | DEHP—No effect. BPA—global decrease in DNA methylation and significant decrease in the expression of | Not described | [ |
| BPA | SH-SY5Y human neuroblastoma cells | 0.1, 1, 10/48, 96 h | 10 µM BPA treatment led to a significant increase in global DNA methylation and expression of | Increased expression of | [ |
| BPA | MCF-10F breast epithelial cells | 1–10 µM/14 days | Increased expression of DNA repair genes and decreased expression of apoptosis genes. Hypermethylation of | Possible interaction with ERβ or a non-classical signaling mechanism | [ |
| BPS | MCF-7 breast adenocarcinoma cancer cell line | 10 nM, 100 nM, 1 µM/24 h | Hypermethylation of transposons. Increase in the DNA methylation at tumor suppressor gene promoters. Upregulation of cancer pathology genes involved in the PI3K/AKT pathway | ER activation of PI3K/AKT pathway | [ |
| ZEN | Human MCF-7 breast adenocarcinoma cancer cell line and MCF-10F breast epithelial cells |
MCF-7: 1, 10, 50 µM/24 h MCF-10F: 0.1, 1, 10 µM/24 h | Significant global DNA methylation increase in MCF-7 cells but not MCF-10F cells. Increased DNMT1 and MGMT in MCF-7 cells. Upregulation of | Disruption of energy and metabolism pathways within the cells | [ |
| ZEN | Germinal vesicle (GV) stage mouse oocytes | 10, 50 µM/12 h | Elevated global DNA methylation but no change in expression of | May directly affect DNA methyltransferase activity | [ |
| ZEN | Porcine oocytes | 5, 10, 30 µM/44 h | Increased global DNA methylation levels and decreased degradation of | Decreased degradation of DNA methyltransferases leading to increased global DNA methylation | [ |
| BDE-209 | Neonatal rat hippocampal neuron primary cultures | 10, 30, 50 μg/ml/24 h | Global decrease in DNA methylation levels. Disrupted cell viability, apoptosis, oxidative stress, cellular signal transduction pathway, and intracellular second messengers | Increased cellular calcium ion content disrupting cell signal transduction pathways | [ |
in vitro and ex vivo studies of EDC-induced DNA histone modification epimutations
| Chemical(s) |
| Concentration/length of exposure | Phenotypic effect(s) | Pathway(s)/mechanism(s) | Citation(s) |
|---|---|---|---|---|---|
|
BPA DEHP | Porcine oocytes |
BPA: 200, 250 µM/26 h DEHP: 250 µM, 500 µM, 750 µM, 1 mM, 5 mM/26 h |
BPA—decreased global H3K4me2 methylation and increased expression of DEHP—no effects | Not described | [ |
| BPA | SH-SY5Y human neuroblastoma cells | 0.1, 1, 10 µM/96 h | Decrease in histone H3K4me3 and H3K9ac. Increase in in expression of | BPA leads to an increase of | [ |
| BPA | MCF-7 human breast cancer cells | 0–1000 nM/6 h | Increase in expression of cancer-associated gene | Increase of | [ |
| DES | MCF-7 breast cancer cell line and ELT3 cell line |
MCF-7 and ELT3: 50, 100 nM/15–60 min ELT3: 10, 50, 100 nM/7 or 10 days | Increased activity of EZH2 by phosphorylation of S21 causes a decrease in H3K27me3 in MCF-7 cells | Aberrant ER-mediated PI3K/AKT activation of EZH2 may alter chromatin structure in the developing uterus to reprogram gene expression in a heritable manner | [ |
| ZEN | Geminal vesicle (GV) stage mouse oocytes | 10, 50 µM/12 h | Decreases in H3K4me2, H3K9me3, and H4K20me1–3 | Changes in histone methylation are disrupting oogenesis, chromatin configuration/compaction, and cell cycle progression leading to an overall decrease in egg competence | [ |
| ZEN | Porcine oocytes | 5, 10, 30 µM/44 h | 30 µM led to overall increases in H3K4me2, H3K9me3, and H3K27me3. Increased expression of | Disrupted H3K4me2, H3K9me3, and H3K27me3 levels cause changes in centromeric heterochromatin domains disrupted interactions between kinetochores and spindle microtubules, disrupted embryonic gene expression, cell lineage segregation, and reduced overall oocytes quality | [ |
| NP OP | THP-1 human monocytes | 10 nM–1 µM/1 h | Suppressed H4 acetylation at the promoter of | Suppressed ERK, JNK, and p38-MAPK pathways in an ER-independent manner. NP may be signaling through PXR or NP and OP are suppressing ERK, JNK, and p38-MAPK pathways through non-classical hormone signaling | [ |
| NP OP | Human myeloid dendritic cells (mDCs) | 0.1 nM–0.1 µM/4, 12, 24, and 48 h | Suppressed | Increased | [ |
| TBT | Bone marrow-derived mouse mesenchymal stem cells | 5, 50 nM/48 h | Decreased levels of H3K27me3 at genes that regulate adipogenesis, including | RXR-dependent suppression of histone modification regulating | [ |
| IOX TBBPA |
| 0.01–1 µM/24 h | Reduced T3-induced expression of | Potential suppression of TH-induced activation of RNAPII transcriptional elongation in TH-responsive genes | [ |
*TNFA, Tumor necrosis factor alpha; **LPS, Lipopolysaccharide.